Antipsychotic medication (older drugs) plus basic psychosocial treatment for psychosis
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$849–1110
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
3
Tier A · 91 studies
Source agreement
comparable
within 2.5×
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at population-level population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources within 2.5x - treat as comparable, not ranked.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 89 studies, varied methods — explore the spread, not a single number.
Health-system
$7,020
median · n=84
Societal
$167
median · n=5
Filter the cohort
$5,867median of 89 studies · IQR $2,354–$14,281 · 9 cost-saving
Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$1601median · 2 studies
range $1427–$1774/DALY. Varied methods — not directly comparable.
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Antipsychotic medication (older drugs) plus basic psychosocial treatment for psychosis? Select a country above, then open its intelligence page.